| 摘要 |
The present invention relates to drug combinations and pharmaceutical compositions for treating cancer such as non-small cell lung carcinoma, said combination comprising (1) at least one substituted-diaryl urea such as BAY 43-9006, (2) at least one taxane such as Paclitaxel (Taxol®), Docetaxel (Taxotere®) and AbraxaneTM and (3) at least one platinum complex antineoplastic nucleic acid binding agent such as carboplatin (Paraplatin®), oxaplatin (Eloxatin®) and cisplatin (Platinol®), where any of these components can be present in the form of a pharmaceutically acceptable salt or other derivative thereof. |
